Hotgen(SH:688068) Xin Lang Cai Jing·2025-10-22 08:15Core Viewpoint - The announcement from Hotgen Biotech indicates that its affiliate, Beijing ShunJing Biopharmaceutical Technology Co., Ltd., has reported positive preliminary results from the Phase Ib clinical study of the innovative drug SGC001 injection for patients with anterior ST-segment elevation myocardial infarction [1] Group 1: Clinical Study Results - SGC001 injection showed effective trends in myocardial protection at doses of 600 mg and 900 mg compared to the placebo group [1] - The median percentage reduction in myocardial infarction area was 20.5% for the 600 mg group and 38.1% for the 900 mg group [1] - The safety and tolerability of SGC001 injection were good, with no occurrences of grade 3 or higher adverse events or serious adverse events reported [1]